Bioorganic & Medicinal Chemistry Letters 21 (2011) 3066–3069

Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl

Synthesis and biological evaluation of benzyl styrylsulfonyl derivatives as potent anticancer mitotic inhibitors

Osama Chahrour [a], Ashraf Abdalla [a], Frankie Lam [a], Carol Midgley [b], Shudong Wang [a,*]

[a] School of Pharmacy and Centre for Biomolecular Sciences, University of Nottingham, Nottingham NG7 2RD, UK
[b] Department of Life Sciences, The Open University, Milton Keynes MK7 6AA, UK

ARTICLE INFO

Article history:
Received 27 January 2011
Revised 9 March 2011
Accepted 9 March 2011
Available online 17 March 2011

Keywords:
Mitotic inhibitor
Polo-like kinase
Serine/threonine kinase
Anticancer therapy

ABSTRACT

We herein report the synthesis, biological activity and structure activity relationship of derivatives of benzylstyrylsulfone, benzylstyrylsulfine and benzylsulfonyl-*N*-phenylacetamide. A lead compound **7** represents a new class of mitotic inhibitors that demonstrates potent anti-proliferative activity and selectively induces cancer cell apoptosis while sparing non-transformed lung fibroblast.

Sodium (*E*)-{*N*-[2-methyloxy-5-(2,4,6-trimethoxy-styryl sulfonyl)methylenephenyl]amino}acetate (ON 01910.Na, Onconova Therapeutics Inc., Fig. 1) is a novel anticancer agent currently in phase I clinical trials in patients. ON 01910 is a cell-cycle inhibitor and selectively causes mitotic arrest by creating spindle abnormalities and abnormal centrosome localization and fragmentation leading to apoptosis in cancer cells. It has been shown to inhibit PLK1 pathway activity at a nanomolar range in a substrate-dependent and ATP-independent manner, although targeting other kinases has also been reported.[1,2] This compound inhibits a broad spectrum of human tumour cell growth with GI_{50} values in the nanomolar range and is active in a number of human xenografts in mice.[3,4] Currently, the drug is in several phase I and II clinical trials in adult patients with a variety of solid tumours as well as hematological malignancies.[5–8] Anti-tumour activity was observed in all phase I trials. Recent phase I studies in human B-cell chronic lymphocytic leukaemia (CLL) demonstrated that ON 01910.Na selectively induced apoptosis in all CLL samples tested and reduced PLK1 activity in the leukeamic cells[3] ON 01910.Na is currently also being tested in phase I combination therapy in patients with solid tumors.

Our efforts to develop small molecule cell-cycle inhibitors for cancer therapy has resulted in the development of several classes of CDK and Aurora kinase inhibitors.[9–13] In the process of designing novel class PLK1 inhibitors we prepared and evaluated the biological activity of ON 01910 and several derivatives. The structure activity relationship established has provided guidance for us to rapidly progress our drug discovery programme. Here, we report the synthesis and biological evaluation of analogue benzylstyrylsulfones, benzylstyrylsulfines and benzylsulfonyl-*N*-phenylacetamides (Class-I, -II and -III, Fig. 1). This study suggests that the benzylstyrylsulfinyl chemotype offers great potential for development of anti-cancer agents.



Figure 1. Structures of ON 01910.Na and the designated derivatives.

The synthetic chemistry employed to prepare Class I–III compounds is outlined in Scheme 1. The synthesis started from 2-(4-methoxy-3-nitrobenzylthio)acetic acid **1**, which can be obtained by halogenation of 1-methoxy-4-methyl-2-nitrobenzene followed by treatment with 2-mercaptoacetic acid.[14,15] 2-(4-Methoxy-3-nitrobenzylsulfonyl)acetic acid **2** or 2-(4-methoxy-3-nitrobenzylsulfinyl)acetic acid **5** were obtained by chemoselective oxidation of **1**. Doebner modification of Knoevenagel condensation[16] between **2** or **5** with substituted aromatic aldehyde in pyridine and catalytic amounts of piperidine yielded the corresponding (*E*)-1-methoxy-2-

* Corresponding author. Tel.: +44 1158466863; fax: +44 01159513412.
E-mail address: shudong.wang@nottingham.ac.uk (S. Wang).

0960-894X/$ - see front matter Crown Copyright © 2011 Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.bmcl.2011.03.041



Scheme 1. Reagents and conditions: (a) H_2O_2, AcOH, 50 °C, 6 h, 98%; (b) aromatic aldehyde, cat. piperidine, pyridine, rt, 36 h, 19–50%; (c) (i) Sulfurous dichloride, EtOAc, reflux, 40 min, 100%; (ii) aniline, anhydrous THF, reflux, 3 h, 80–91%; (d) H_2O_2, AcOH, 0 °C, 6 h, 95%; (e) Fe^0, AcOH/MeOH (1:2), reflux, 3 h, 95–96%.

Table 1
Structure and growth inhibitory activity of selected compounds against human tumour cancer cells

Compd	Structure		Cytotoxicity, 72 h MTT (GI_{50}, μM)[a]				
	R	R′	T47D	MDA-468	HCT-116	MCF-7	MRC-5
3a	2,4,6-$(OMe)_3$	NO_2	NT	NT	0.66	0.88	2.91
3b	2,3,4-$(OMe)_3$	NO_2	>30	21.89	27.85	>30	>0
3c	2,6-$(OMe)_2$	NO_2	>30	5.46	10.22	13.71	>30
3d	3,5-$(OMe)_2$	NO_2	>30	16.46	>30	>30	>30
3e	2,4,6-$(OMe)_3$	NH_2	NT	0.03	<0.01	<0.01	0.08
3f	2,3,4-$(OMe)_3$	NH_2	5.90	3.48	5.31	5.95	>30
3g	2,6-$(OMe)_2$	NH_2	0.05	0.06	0.02	0.04	17.09
3h	3,5-$(OMe)_2$	NH_2	0.53	0.52	0.54	0.49	>30
3i	2,4,6-$(OMe)_3$	NHCOMe	NT	NT	0.15	0.35	0.81
3j	2,4,6-$(OMe)_3$	$NHCH_2CO_2H$	<0.01	0.02	0.05	0.05	0.71
4a	H	NO_2	>30	>30	>30	>30	>30
4b	2,4,6-$(Me)_3$	NO_2	>30	>30	7.91	>30	27.96
4c	2,4,6-$(OMe)_3$	NO_2	>30	>30	18.80	>30	>30
4d	2,5-$(OMe)_2$	NO_2	>30	>30	>30	>30	>30
4e	NO_2	NO_2	>30	>30	>30	>30	>30
4f	H	NH_2	>30	>30	>30	>30	>30
4g	2,4,6-$(Me)_3$	NH_2	>30	> 30	>30	>30	>30
7	2,4,6-$(OMe)_3$	—	0.06	<0.01	<0.01	<0.01	>30

[a] Values are means of at least three independent determinations. NT: not tested.

nitro-4-(styrylsulfonylmethyl)benzene **3a**, **3b**, **3c** and **3d** (R′ = NO_2, Scheme 1 and Table 1) or (*E*)-1-methoxy-2-nitro-4-(styrylsulfinylmethyl)benzene **6** (R = 2,4,6-trimethoxyl). Reduction of **3a**, **3b**, **3c** or **3d**, as well as **6** resulted in their respective anilino derivatives **3e**, **3f**, **3g**, **3h** and **7**. Acylation of **3e** (R′ = NH_2, R = 2,4,6-$(OMe)_3$) with acylchloride afforded **3i** (R′ = NHCOMe, R = 2,4,6-$(OMe)_3$, Table 1). Treatment of **3e** with ethyl 2-bromoacetate in the presence of sodium acetate followed by hydrolysis in aqueous sodium carbonate yielded **3j** (R′ = $NHCH_2COOH$, R = 2,4,6-$(OMe)_3$, e.g. ON 01910).

To prepare chemotype-III sulfonyl-*N*-phenyl acetamides (Fig. 1) 2-(4-methoxy-3-nitrobenzylsulfonyl)acetic acid **2** was converted to 2-(4-methoxy-3-nitrobenzylsulfonyl)acetyl chloride. The later, treated with various substituted anilines, resulted in **4a**, **4b**, **4c**, **4d** and **4e**. Reduction of **4a** and **4b** in the presence of tin chloride generated **4f** and **4g,** respectively.

Anti-proliferative activity was assessed against colorectal carcinoma HCT-116, breast carcinoma MCF-7, MDA-468, MDA-231 and T74D using a standard 72-h MTT cytotoxicity assay.[17] The compounds were also tested against non-transformed lung fibroblast MRC-5. The results are summarized in Table 1.

Most (*E*)-2-methoxy-5-(styrylsulfonylmethyl)anilines, particularly **3e**, **3g**, **3h**, **3i** and **3j**, exhibited potent anti-proliferative activity with GI_{50} <1 μM in cancer cells, except compound **3f** (R = 2,3,4-$(OMe)_3$) which has only modest activity (GI_{50} <5 μM). **3e** and **3j** (ON 01910) were the most potent anti-proliferative agents with GI_{50} below 0.1 μM; the 2,4,6-trimethoxy substituted styryl moiety seems important for the optimum potency observed. Interestingly, MRC-5 non-transformed cells appeared insensitive towards **3g** and **3h**, being <280- and <80-fold less cytotoxic compared with the cancer cells tested. Replacement of the amino group on benzyl moiety in **3f**, **3g** and **3h** with nitro group resulting in corresponding analogue **3b**, **3c** and **3d** abolished the activity. Compound **3a** which contained the favourable 2,4,6-trimethoxylstyryl moiety gained some degree of activity compared to its analogues **3b–3d**. Replacement of the sulfonyl in **3e** with sulfinyl afforded (*E*)-2-methoxy-5-((2,4,6-trimethoxystyrylsulfinyl)methyl)aniline **7**, which showed the excellent anti-tumour activity, being compa-

Table 2
Time course MTT assay in MDA-468 cells

Time (h)	Cytotoxicy, MTT (GI_{50}, μM)[a]	
	3j	**7**
24	0.601 ± 0.065	0.559 ± 0.095
48	0.302 ± 0.021	0.137 ± 0.023
72	0.014 ± 0.003	<0.01

[a] Represent as the mean of three independent assay ± SD.



Figure 2. Cell cycle analysis of MDA-468 cells following treatment with compound **3j** or **7** for a period of 20 h at the concentrations shown. Vertical bars represent the mean ± SD of three independent experiments. Values significantly (p <0.05) different from DMSO vehicle control are marked with an asterisk (∗).

rable to **3e**. Significantly, compound **7** selectively killed cancer cells while sparing non-transformed MRC-5 cells. Replacement of styrylsulfonyl with sulfonyl-*N*-phenylacetamide was poorly tolerated and compounds **4a–4g** were completely inactive in the assay.

The structure activity relationship analysis suggests that the styrylbenzylsulfonyl or styrylbenzylsulfinyl moiety is essential for potency, replacement with sulfonyl-*N*-phenylacetamide showing a dramatic loss in activity. Substitutions on the styryl ring system were generally found to be tolerated, although 2,4,6-trimethoxyl was the most favourable function. Substitutions with electron donating group on the benzyl ring system may be amenable to optimization.

The primary cellular mode of action of **7** was investigated when compared with **3j**. The time-dependent growth inhibitory activity was examined in MDA468 cells. As shown in Table 2, both compounds exhibited comparable cytotoxicity and increased potency with extended time. We next examined the cell-cycle effects.[18] Analyses by flow cytometry exposed severe perturbation of cell-cycle progression following treatment of cells with ⩾0.5 μM of **3j** or **7** (Fig. 2). 20 h post treatment of MDA-468 cells with **3j** at 0.5 μM (GI_{50}) and 1 μM ($2 \times GI_{50}$) resulted in accumulation of G2/M events—58% and 84%, respectively. This was consistent with ON 01910 mechanism of action described previously.[15,3] Compound **7** demonstrated a similar cell-cycle profile; treatment of the cells with **7** at 0.5 μM (GI_{50}) and 1.0 μM ($2 \times GI_{50}$) causing 77% and 85% cells with G2/M DNA content, respectively. Induction of apoptosis by the compounds was further analyzed by annexinV/PI double staining[18] in MDA-468 cells following treatment with either **3j** or **7** at 0.5 μM, 1 μM and 10 μM for a period of 20 h. Both **3j** and **7** induced significant numbers of apoptotic cells, effectively starting from 0.5 μM in a dose-dependent manner (Fig. 3).



Figure 3. Apoptosis of MDA-468 cells following treatment with **3j** or **7** for 20 h at concentrations indicated. The percentage of cells undergoing apoptosis was defined as the sum of early apoptosis (annexin V-positive cells) and late apoptosis (annexin V-positive and PI-positive cells). Vertical bars represent the mean ± SD of three independent experiments. Values significantly (p <0.05) different from DMSO vehicle control are marked with an asterisk (∗).



Figure 4. Analysis of stability under MCF-7 and MRC-5 cell culture conditions using HPLC and HR-MS methods. Vertical bars represent the mean ± SD of two independent experiments.

To investigate cellular metabolic stability compound **7** (1 μM) was incubated in cell culture medium in the presence or absence of MCF-7 and MRC-5 cells respectively. Aliquots were taken at the time points and stabilised. After centrifugation, the samples were analysed by HPLC and HR-MS. As shown in Fig. 4. Compound **7** was stable under MCF-5 and MRC5 cell culture conditions and no conversion to **3j** was detected.

In conclusion, a series of benzylstyrylsulfonyl derivatives and benzylsulfonyl-*N*-phenylacetamides were prepared[19] and the structure activity relationships were established. (*E*)-2-Methoxy-5-((2,4,6-trimethoxystyrylsulfinyl)methyl)aniline **7** possessed potent anti-proliferative activity against cancer cell lines, being comparable to **3j**. Compound **7** showed similar cell-cycle effects to **3j** and was capable of inducing cancer cells to apoptosis.

Acknowledgments

O. Chahrour and A. Abdalla thank University of Damascus and Islamic Development Bank (IDB) for their respective studentships.

References and notes

1. Gumireddy, K.; Reddy, M. V.; Cosenza, S. C.; Boominathan, R.; Baker, S. J.; Papathi, N.; Jiang, J.; Holland, J.; Reddy, E. P. *Cancer Cell* **2005**, *7*, 275–286.
2. Strebhardt, K. *Nat. Rev. Drug Discov.* **2010**, *9*, 643–660.
3. Schoffski, P. *Oncologist* **2009**, *14*, 559–570.
4. Chun, A. W.; Cosenza, S. C.; Taft, D. R.; Maniar, M. *Cancer Chemother. Pharmacol.* **2009**, *65*, 177–186.
5. Reagan-Shaw, S.; Ahmad, N. *IUBMB Life* **2005**, *57*, 677–682.

6. Jimeno, A.; Li, J.; Messersmith, W. A.; Laheru, D.; Rudek, M. A.; Maniar, M.; Hidalgo, M.; Baker, S. D.; Donehower, R. C. *J. Clin. Oncol.* **2008**, *26*, 5504–5510.
7. Jimeno, A.; Chan, A.; Cusatis, G.; Zhang, X.; Wheelhouse, J.; Solomon, A.; Chan, F.; Zhao, M.; Cosenza, S. C.; Ramana Reddy, M. V.; Rudek, M. A.; Kulesza, P.; Donehower, R. C.; Reddy, E. P.; Hidalgo, M. *Oncogene* **2009**, *28*, 610–618.
8. Prasad, A.; Park, I. W.; Allen, H.; Zhang, X.; Reddy, M. V.; Boominathan, R.; Reddy, E. P.; Groopman, J. E. *Oncogene* **2009**, *28*, 1518–1528.
9. Wang, S.; McClue, S. J.; Ferguson, J. R.; Hull, J. D.; Stokes, S.; Parsons, S.; Westwood, R.; Fischer, P. M. *Tetrahedron: Asymmetry* **2001**, *12*, 2891–2894.
10. Wang, S.; Wood, G.; Meades, C.; Griffiths, G.; Midgley, C.; McNae, I.; McInnes, C.; Anderson, S.; Jackson, W.; Mezna, M.; Yuill, R.; Walkinshaw, M.; Fischer, P. M. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 4237–4240.
11. Wang, S.; Meades, C.; Wood, G.; Osnowski, A.; Anderson, S.; Yuill, R.; Thomas, M.; Mezna, M.; Jackson, W.; Midgley, C.; Griffiths, G.; Fleming, I.; Green, S.; McNae, I.; Wu, S. Y.; McInnes, C.; Zheleva, D.; Walkinshaw, M. D.; Fischer, P. M. *J. Med. Chem.* **2004**, *47*, 1662–1675.
12. Wang, S.; Griffiths, G.; Midgley, C. A.; Barnett, A. L.; Cooper, M.; Grabarek, J.; Ingram, L.; Jackson, W.; Kontopidis, G.; McClue, S. J.; McInnes, C.; McLachlan, J.; Meades, C.; Mezna, M.; Stuart, I.; Thomas, M. P.; Zheleva, D. I.; Lane, D. P.; Jackson, R. C.; Glover, D. M.; Blake, D. G.; Fischer, P. M. *Chem. Biol.* **2010**, *17*, 1111–1121.
13. Wang, S.; Midgley, C. A.; Scaerou, F.; Grabarek, J. B.; Griffiths, G.; Jackson, W.; Kontopidis, G.; McClue, S. J.; McInnes, C.; Meades, C.; Mezna, M.; Plater, A.; Stuart, I.; Thomas, M. P.; Wood, G.; Clarke, R. G.; Blake, D. G.; Zheleva, D. I.; Lane, D. P.; Jackson, R. C.; Glover, D. M.; Fischer, P. M. *J. Med. Chem.* **2010**.
14. Reddy, P. E.; Reddy, R. M. V.; Bell, S. C.; Onconova Therapeutics, Inc. Temple University, USA, WO2003072062.
15. Reddy, M. V.; Mallireddigari, M. R.; Cosenza, S. C.; Pallela, V. R.; Iqbal, N. M.; Robell, K. A.; Kang, A. D.; Reddy, E. P. *J. Med. Chem.* **2008**, *51*, 86–100.
16. Inokuchi, T.; Kawafuchi, H. *J. Org. Chem.* **2006**, *71*, 947–953.
17. Mosmann, T. *J. Immunol. Methods* **1983**, *65*, 55–63.
18. *Cell cycle analysis*: Exponentially growing cells were seeded at a density of 4×10^5 and incubated at 37 °C in a humidified, 5% CO_2 atmosphere overnight. Following 20 h incubation with compound at appropriate concentrations, the cells were collected. Cell pellets were washed once with cold PBS and re-suspended in 0.4 ml hypotonic fluorochrome solution. Cell cycle status was analysed using a Beckman Coulter EPICS-XL MCL™ flow cytometer and data analyzed using EXPO32™ software.
AnnexinV/propidium iodide (PI) staining: was used to quantitatively determine the percentage of apoptotic cells. Cells (4×10^5) per well were treated with compounds after overnight culture. Sample preparation, staining, and analysis were performed following the protocol provided by BD (BD Bioscience).
19. *Synthesis of lead compound* **7**: 2-(4-Methoxy-3-nitrobenzylthio) acetic acid (**5**): To a solution of 2-mercaptoacetic acid (0.35 mL, 5 mmol) in 100 mL of methanol, sodium carbonate (0.40 g) and 4-(bromomethyl)-1-methoxy-2-nitrobenzene (0.62 g, 2.5 mmol) was added, and the mixture was refluxed for 1 h, cooled, and spilled over ice (300 g). The pH was adjusted to 3 by addition of 2 N HCl aq to give a yellow precipitate. Recrystallisation from Pet/EtOAc afforded **5** as pale yellow crystals (0.56 g, 88% yield). mp 128–131 °C; ^{1}H NMR (DMSO-d_6) δ 3.14 (s, 2H, CH_2), 3.83 (s, 2H, CH_2), 3.91 (s, 3H, OCH_3) 7.33 (d, J = 8.4 Hz, 1H, Ph-H), 7.61 (dd, J = 8.4, 2.0 Hz, 1H, Ph-H), 7.83 (d, J = 2.0 Hz, 1H, Ph-H), 12.62 (s, 1H, CO_2H). ^{13}C NMR (DMSO-d_6) δ 33.04, 34.39, 57.15, 114.86, 125.58, 130.97, 135.45, 139.29, 151.54, 171.65. HRMS (ESI$^-$) m/z 256.0065 $[M-1]^-$, $C_{10}H_{11}NO_5S$ requires 257.0358.
*2-(4-Methoxy-3-nitrobenzylsulfinyl) acetic acid (**6**)*: solution of 2-(4-methoxy-3-nitrobenzylthio) acetic acid (0.26 g, 1 mmol) in 20 mL of acetic acid was cooled to 0 °C on an ice bath. Hydrogen peroxide 35% w/v (0.15 mL, 1.5 mmol) was added and the mixture was stirred at 0 °C for 6 h. After concentration the reaction mixture was purified by flash chromatography using EtOAc to yield **6** as a pale yellow solid (0.26 g, 95% yield); mp 67–68 °C; ^{1}H NMR (DMSO-d_6) δ 3.52 (d, J = 14.4 Hz, 1H, CH_2), 3.88 (d, J = 14.4 Hz, 1H, CH_2), 3.94 (s, 3H, OCH_3), 4.11 (d, J = 12.8 Hz, 1H, CH2), 4.28 (d, J = 12.8 Hz, 1H, CH_2), 7.40 (d, J = 8.8 Hz, 1H, Ph-H), 7.61 (dd, J = 8.8, 2.17 Hz, 1H, Ph-H), 7.85 (d, J = 2.17 Hz, 1H, Ph-H). ^{13}C NMR (DMSO-d_6) δ 55.12, 55.82, 57.24, 115.02, 123.69, 127.08, 136.97, 139.33, 152.35, 167.91. HRMS (ESI$^-$) m/z 272.0130 $[M-1]^-$, $C_{10}H_{11}NO_6S$ requires 273.0307.
*(E)-2-Methoxy-5-((2,4,6-trimethoxystyrylsulfinyl)methyl)aniline (**7**)*: 2-(4-methoxy-3-nitrobenzylsulfinyl)acetic acid (0.55 g, 2 mmol) and 2,4,6-trimethoxybenzaldehyde (0.49 g, 2.5 mmol) were dissolved in mixture of anhydrous pyridine (10 mL) and anhydrous piperidine (few drops). After stirring at rt for 36 h the mixture was evaporated to give gummy brown residue which was dissolved in ethyl acetate (20 mL) and washed with 2 N NaOH aq (10 mL), 2 N HCl aq (10 mL), and distilled water (10 mL). After being dried over anhydrous $MgSO_4$, the organic solution was evaporated to afford a mixture of (*E*)-1,3,5-trimethoxy-2-(2-(4-methoxy-3nitrobenzylsulfinyl)-vinyl)benzene. Without further purification the compound was dissolved in hot methanol (10 mL) and treated with Iron powder (10 mmol) in acetic acid (5 mL). After refluxing for 3 h, the mixture was treated with ammonia solution (2 N aq) and extracted with EtOAc (20 mL). The organic layer was concentrated and purified by flash chromatography (EtOAc) to give **7** as a pale brown solid (0.30 g, 40% yield); mp 117–119 °C; ^{1}H NMR (Acetone-d_6) δ 3.16 (s, 3H, OCH_3), 3.85 (s, 2H, CH_2), 3.87 (s, 3H, OCH_3), 3.90 (s, 6H, $OCH_3 \times 2$), 6.29 (s, 2H, Ph-H), 6.61(dd, J = 8.0, 2.0 Hz, 1H, Ph-H), 6.73 (d, J = 2.0 Hz, 1H, Ph-H), 6.80 (d, J 8.0 Hz, 1H, Ph-H), 7.26 (d, J = 15.6 Hz, 1H, CH), 7.45 (d, J = 15.6 Hz, 1H, CH). ^{13}C NMR (Acetone-d_6) δ 54.90, 54.99, 55.31, 61.28, 90.61, 105.50, 110.17, 115.84, 118.91, 123.50, 125.30, 131.25, 137.80, 147.50, 160.34, 162.50. HRMS (ESI$^+$) m/z 377.9233 $[M+1]^+$, $C_{19}H_{23}NO_5S$ requires 377.1297. Anal. RP-HPLC (Kromasil C_{18} column, 250 × 4.6 mm, H_2O/CH_3CN containing 0.3% CF_3COOH): t_R = 2.4 min, purity >99%.